← Leaderboards
Samuel R Denmeade
Johns Hopkins University
$5,431,317
Attributed
$6,394,687
Total exposure
7
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.5M · FY2006–25$5M$3.8M$2.5M$1.3M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,203,468 · 9
By mechanism
P50$11,052,622 · 4
R01$4,068,919 · 3
U54$670,455 · 1
R21$411,472 · 1
Top collaborators
- Sushant Krishna Kachhap4 shared
- Shawn Lupold2 shared
- David Esteban Sanin Pena2 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Ben H Park$14,510,999
- Theodore P Abraham$7,840,836
- Sushant Krishna Kachhap$757,635
- Suzanne Gartner$7,702,037
- James G. Herman$8,069,882
Others in their field
Top investigators on “Malignant Neoplasm Of Prostate”
- David Heimbrook · Leidos Biomedical Research, Inc.$255,843,614
- Leonard Freedman · Leidos Biomedical Research, Inc.$63,277,106
- Walter John Curran · Thomas Jefferson University$61,298,085
- Norman Wolmark · Nsabp Foundation, Inc.$54,888,134
- James J. Dignam · University Of Chicago$48,310,409
- Laurence H Baker · University Of Michigan At Ann Arbor$43,366,962
Research focus
Malignant Neoplasm Of ProstateCellsResponseIn VitroGrowthDoseProstate Cancer CellTumorAndrogensResistanceAndrogen ReceptorEnvironmentProgramsCastrationTestosteroneBaseMalignant NeoplasmsReceptor SignalingClinical ResearchIn VivoMediatingMetastatic Prostate CancerAndrogen TherapyExposure To
Grant awards (29)
SPORE in Prostate Cancer$2,264,776
P50 · FY2025 · CA · contact PI
Project 1: Combined Suppression of MYC as therapy for CRPC: the COSMYC trial$377,111
P50 · FY2025 · CA · contact PI
Administrative Core$253,657
P50 · FY2025 · CA · contact PI
Androgen Activation of Innate Immune Signaling to Enhance Prostate Cancer Immune Response$1
R01 · FY2025 · CA
SPORE in Prostate Cancer$2,190,123
P50 · FY2024 · CA · contact PI
Androgen Activation of Innate Immune Signaling to Enhance Prostate Cancer Immune Response$498,873
R01 · FY2024 · CA
Project 1: Combined Suppression of MYC as therapy for CRPC: the COSMYC trial$366,533
P50 · FY2024 · CA · contact PI
Administrative Core$246,540
P50 · FY2024 · CA · contact PI
The Role of Myeloid-Derived Suppressor Cells in Resistance to Bipolar Androgen Therapy in Patients with Advanced Prostate Cancer$181,813
R21 · FY2024 · CA
Androgen Activation of Innate Immune Signaling to Enhance Prostate Cancer Immune Response$488,578
R01 · FY2023 · CA
The Role of Myeloid-Derived Suppressor Cells in Resistance to Bipolar Androgen Therapy in Patients with Advanced Prostate Cancer$229,659
R21 · FY2023 · CA
Androgen Activation of Innate Immune Signaling to Enhance Prostate Cancer Immune Response$527,817
R01 · FY2022 · CA
SPORE in Prostate Cancer$1,478,967
P50 · FY2020 · CA · contact PI
SPORE in Prostate Cancer$1,881,489
P50 · FY2018 · CA · contact PI
Bipolar Androgen Therapy for Progressive Castrate Resistant Prostate Cancer$261,450
R01 · FY2018 · CA · contact PI
SPORE in Prostate Cancer$1,993,426
P50 · FY2017 · CA · contact PI
Bipolar Androgen Therapy for Progressive Castrate Resistant Prostate Cancer$261,450
R01 · FY2017 · CA · contact PI
Bipolar Androgen Therapy for Progressive Castrate Resistant Prostate Cancer$261,450
R01 · FY2016 · CA · contact PI
Bipolar Androgen Therapy for Progressive Castrate Resistant Prostate Cancer$261,450
R01 · FY2015 · CA · contact PI
Bipolar Androgen Therapy for Progressive Castrate Resistant Prostate Cancer$261,450
R01 · FY2014 · CA · contact PI
Fibroblast Activation Protein-alpha Activated Anti-Stromal Prodrug Therpay for Ca$311,600
R01 · FY2010 · CA · contact PI
Synthesis and MAPK Kinase Inhibitiory Activities in Prostate Tumors$145,442
U54 · FY2010 · CA · contact PI
Fibroblast Activation Protein-alpha Activated Anti-Stromal Prodrug Therpay for Ca$311,600
R01 · FY2009 · CA · contact PI
Synthesis and MAPK Kinase Inhibitiory Activities in Prostate Tumors$142,952
U54 · FY2009 · CA · contact PI
Fibroblast Activation Protein-alpha Activated Anti-Stromal Prodrug Therpay for Ca$311,600
R01 · FY2008 · CA · contact PI
Synthesis and MAPK Kinase Inhibitiory Activities in Prostate Tumors$151,087
U54 · FY2008 · CA · contact PI
Fibroblast Activation Protein-alpha Activated Anti-Stromal Prodrug Therpay for Ca$311,600
R01 · FY2007 · CA · contact PI
Synthesis and MAPK Kinase Inhibitiory Activities in Prostate Tumors$149,912
U54 · FY2007 · CA · contact PI
Full Project 2: Synthesis and MAPK Kinase Inhibitiory Activities in Vitro and In$81,062
U54 · FY2006 · CA · contact PI